<DOC>
	<DOCNO>NCT00003377</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Paclitaxel cisplatin may increase effectiveness radiation therapy make tumor cell sensitive radiation . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose paclitaxel give radiation therapy cisplatin see well work treat patient cancer cervix spread lymph node pelvis abdomen .</brief_summary>
	<brief_title>Radiation Therapy , Paclitaxel , Cisplatin Treating Patients With Cancer Cervix</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxicity extend field radiotherapy concurrent paclitaxel cisplatin chemotherapy ( radiation sensitization ) patient previously untreated carcinoma cervix metastatic para-aortic lymph node . - Determine maximum tolerate dose paclitaxel combine cisplatin plus extended field radiotherapy patient population . - Determine effect treatment regimen progression-free survival , overall survival , site recurrence ( local v distant ) patient . OUTLINE : This multicenter , dose-escalation study paclitaxel . Patients receive external beam radiotherapy ( RT ) para-aortic node pelvis daily 5 week ; RT must complete within 8 week initiation . During external beam RT , intracavitary radiation administer 1-5 time . Concurrently external beam RT , patient receive paclitaxel IV 1 hour follow immediately cisplatin IV day 1 , 8 , 15 , 22 , 29 , 36 . Cohorts 3-6 patient receive escalate dos paclitaxel maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter time recurrence death . PROJECTED ACCRUAL : A total 20-40 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove previously untreated invasive carcinoma uterine cervix Squamous cell carcinoma Adenosquamous carcinoma Adenocarcinoma TNM classification stage IIIB IVA ( FIGO classification stage IB , IIA , IIB , IIIA , IIIB , IVA ) Cytologically histologically prove metastasis paraaortic lymph nod No 8 week since diagnosis No metastases scalene node , intraperitoneal metastasis , metastasis organ outside radiation field time original clinical surgical stag Negative CT scan chest Patients ureteral obstruction must treat stent nephrostomy tube PATIENT CHARACTERISTICS : Age : 18 Performance status : GOG 02 Life expectancy : At least 6 month Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time normal SGOT great 3 time normal Renal : Creatinine le 2.0 mg/dL No renal abnormality ( e.g. , pelvic kidney , horseshoe kidney , renal transplantation ) require modification radiation field Other : Not pregnant No septicemia severe infection No invasive malignancy within past 3 year except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cytotoxic chemotherapy malignancy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy malignancy No prior radiotherapy pelvis abdomen Surgery : Not specify Other : No prior therapy malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
</DOC>